Ross Givens here with a hot new trade opportunity that I believe has the potential to gain as much as 207% in a matter of months.
The opportunity comes on a small biotech stock that just took a 35% tumble after its latest drug trial didn’t go quite as well as expected.
But there’s a few key reasons why I believe this drastic dip is an overreaction…
And why right now is such a great time to get in.
First, the drug that didn’t perform up to snuff isn’t being scrapped.
In fact, the “disappointing” drug trial results really weren’t that bad — only about 5% less than they were expecting…
And the firm is already starting a new study to test this particular drug again in a new group of patients.
Second, this isn’t the firm’s only drug in the pipeline.
It’s actually one of eight new drugs currently under development.
Third, and perhaps most importantly, a key insider at this company just made a huge personal investment to take advantage of this pullback in the stock’s price.
When I say huge…
I mean $4.59 million huge.
This guy knows what he’s doing, too.
His last investment into this company is up 235% since last April.
And the $5.6 million he invested in another biotech stock just two months ago has already grown 106%.
Finally, the technical setup on this stock is picture perfect…
And in the video, I’m showing you exactly what I mean when I say it’s hit “critical mass.”
All in all, I believe this trade could easily triple your money within the next six months.
So if you want to know more about my method for following these types of savvy insiders to huge profits AND discover how you can get your hands on this ticker right now…